

Circulating Tumor Cells Market Expected to Reach \$17.96 Billion by 2022 with CAGR of 19.2%

Circulating Tumor Cells Market is accounted for \$4.41 billion in 2015 and is expected to reach \$17.96 billion by 2022 growing at a CAGR of 19.2 % by 2022

PUNE, MAHARASHTRA, INDIA, December 16, 2016 /EINPresswire.com/ -- <u>Circulating Tumor Cells</u> Industry

Description

Global Circulating Tumor Cells Market is accounted for \$4.41 billion in 2015 and is expected to reach \$17.96 billion by 2022 growing at a CAGR of 19.2 % from 2015 to 2022. The rising demand for high Benefit-Cost Ratio (BCR) associated with CTCs prognostic technology is the major factor boosting the market growth. Furthermore, advancements in biomedical imaging and bioengineering technology are some of the key factors driving the market. However, high cost associated with the diagnosing and reluctance among people towards adopting highly developed prognostic technologies inhibit the market growth. The recent trends in global Circulating Tumor Cells are strengthening distribution network of CTCs prognostic technologies in emerging economies and the technical advancement of CTCs-based customized medicines.

Tumor cell detection is the foremost product segment primarily due to the advantages related with therapeutic monitoring and high procedure prices. North America region is expected to witness highest growth rate during the forecast period due to increasing demand in number of research projects. In addition, the U.S. Government also supports research by funding various institutes, which grant research funds.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/456579-circulating-tumor-cells-global-market-outlook-2015

Some of the key players in the market include

Adnagen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept Inc., Biofluidica, Canopus Biosciences, CellTraffix Inc., Clearbridge BioMedics, Creatv Microtech Inc., Cynvenio Biosystems Inc., Epic Biosciences, Fluxion Biosciences., Greiner Bio-One GmbH, Ikonisys Inc., IV Diagnostics Inc., Janssen Diagnostics, Miltenyi Biotech and Nanostring Technologies Inc.

Technologies Covered:

- Tumor Cell Enrichment
- o Filtration
- o Centrifugation
- o Immunological and Immunomagnetic
- Tumor Cell Detection
- o Molecular
- o Optical

Applications Covered:

- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Applications

Leave a Query @ https://www.wiseguyreports.com/enquiry/456579-circulating-tumor-cells-global-market-outlook-2015

Regions Covered:

- North America
- o US
- o Canada
- o Mexico
- Europe
- o Germany
- o France
- o Italy
- o UK
- o Spain
- o Rest of Europe
- Asia Pacific
- o Japan
- o China
- o India
- o Australia
- o New Zealand
- o Rest of Asia Pacific
- Rest of the World
- o Middle East
- o Brazil
- o Argentina
- o South Africa
- o Egypt

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=456579

Continued...

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Norah Trent

wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.